Vivos Therapeutics
VVOS
27 hedge funds and large institutions have $630K invested in Vivos Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.
500% more call options, than puts
Call options by funds: $6K | Put options by funds: $1K
0.1% less ownership
Funds ownership: 0.37% → 0.27% (-0.1%)
10% less funds holding
Funds holding: 30 → 27 (-3)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
54% less capital invested
Capital invested by funds: $1.38M → $630K (-$749K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
+$8.67K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$7.15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.34K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.13K |
| 5 |
Renaissance Technologies
New York
|
+$1.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$236K |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$51K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$27K |
| 4 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$26K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$9.99K |
VVOS Hedge Fund Activity: Q4 2022 in Review
27 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q4 2022, worth a combined $630K — down 54% from $1.38M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VVOS and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Lincoln National Corp, opening a new position worth an estimated $8.67K. The largest seller was Russell Investments Group, exiting entirely with an estimated $236K sold.
- 27 institutional investors held Vivos Therapeutics (VVOS) as of Q4 2022, down from 30 in Q3 2022.
- Funds reported $630K of Vivos Therapeutics stock for Q4 2022, down 54% quarter-over-quarter.
- 3 funds opened new Vivos Therapeutics positions in Q4 2022 and 6 closed out, a net change of -3 holders.
- The largest Vivos Therapeutics buyer in Q4 2022 was Lincoln National Corp, an estimated $8.67K added.
- The largest Vivos Therapeutics seller in Q4 2022 was Russell Investments Group, an estimated $236K sold.
Based on aggregated 13F filings for Q4 2022.